SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

ChromaDex Corp. – ‘10-Q’ for 10/1/16 – ‘EX-10.5’

On:  Thursday, 11/10/16, at 4:08pm ET   ·   For:  10/1/16   ·   Accession #:  1654954-16-3772   ·   File #:  1-37752

Previous ‘10-Q’:  ‘10-Q/A’ on 8/26/16 for 4/2/16   ·   Next:  ‘10-Q’ on 5/11/17 for 4/1/17   ·   Latest:  ‘10-Q’ on 11/8/23 for 9/30/23   ·   4 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/10/16  ChromaDex Corp.                   10-Q       10/01/16   69:5M                                     Blueprint/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    529K 
 5: EX-10.1     Material Contracts                                  HTML     51K 
14: EX-10.10    Material Contracts                                  HTML     29K 
 6: EX-10.2     Material Contracts                                  HTML     37K 
 7: EX-10.3     Material Contracts                                  HTML     68K 
 8: EX-10.4     Material Contracts                                  HTML    175K 
 9: EX-10.5     Material Contracts                                  HTML     36K 
10: EX-10.6     Material Contracts                                  HTML    119K 
11: EX-10.7     Material Contracts                                  HTML     29K 
12: EX-10.8     Material Contracts                                  HTML     30K 
13: EX-10.9     Material Contracts                                  HTML     52K 
 2: EX-31.1     Certification Pursuant to Rule 13A-14(A)/15D-14(A)  HTML     24K 
                Certifications Section 302 of the Sarbanes-Oxly                  
                Act of 2002                                                      
 3: EX-31.2     Certification Pursuant to Rule 13A-14(A)/15D-14(A)  HTML     24K 
                Certifications Section 302 of the Sarbanes-Oxly                  
                Act of 2002                                                      
 4: EX-32.1     Certificate Pursuant to Section 18 U.S.C. Pursuant  HTML     21K 
                to Section 906 of the Sarbanes-Oxley Act of 2002                 
21: R1          Document and Entity Information                     HTML     44K 
22: R2          Condensed Consolidated Balance Sheets (Unaudited)   HTML     96K 
23: R3          Condensed Consolidated Balance Sheets (Unaudited)   HTML     31K 
                (Parenthetical)                                                  
24: R4          Condensed Consolidated Statements of Operations     HTML     68K 
                (Unaudited)                                                      
25: R5          Condensed Consolidated Statement of Stockholders'   HTML     74K 
                Equity (Unaudited)                                               
26: R6          Condensed Consolidated Statement of Stockholders'   HTML     22K 
                Equity (Parenthetical)                                           
27: R7          Condensed Consolidated Statements of Cash Flows     HTML    116K 
                (Unaudited)                                                      
28: R8          Interim Financial Statements                        HTML     24K 
29: R9          Nature of Business and Liquidity                    HTML     25K 
30: R10         Significant Accounting Policies                     HTML     52K 
31: R11         Reverse Stock Split                                 HTML     21K 
32: R12         Earnings Per Share Applicable to Common             HTML     37K 
                Stockholders                                                     
33: R13         Loan Payable                                        HTML     41K 
34: R14         Employee Share-Based Compensation                   HTML     41K 
35: R15         Stock Issuance                                      HTML     31K 
36: R16         Business Segments                                   HTML    120K 
37: R17         Related Party Transactions                          HTML     28K 
38: R18         Commitments and Contingencies                       HTML     30K 
39: R19         Subsequent Events                                   HTML     25K 
40: R20         Significant Accounting Policies (Policies)          HTML     56K 
41: R21         Significant Accounting Policies (Tables)            HTML     51K 
42: R22         Earnings Per Share Applicable to Common             HTML     38K 
                Stockholders (Tables)                                            
43: R23         Loan Payable (Tables)                               HTML     32K 
44: R24         Employee Share-Based Compensation (Tables)          HTML     38K 
45: R25         Stock Issuance (Tables)                             HTML     23K 
46: R26         Business Segments (Tables)                          HTML    115K 
47: R27         Commitments and Contingencies (Tables)              HTML     26K 
48: R28         Nature of Business and Liquidity (Details           HTML     30K 
                Narrative)                                                       
49: R29         Significant Accounting Policies (Details)           HTML     91K 
50: R30         Significant Accounting Policies (Details 1)         HTML     32K 
51: R31         Reverse Stock Split (Details Narrative)             HTML     23K 
52: R32         Earnings Per Share Applicable to Common             HTML     43K 
                Stockholders (Details)                                           
53: R33         Loan Payable (Details)                              HTML     29K 
54: R34         Loan Payable (Details 1)                            HTML     39K 
55: R35         Loan Payable (Details Narrative)                    HTML     25K 
56: R36         Employee Share-Based Compensation (Details)         HTML     69K 
57: R37         Employee Share-Based Compensation (Details 1)       HTML     30K 
58: R38         Employee Share-Based Compensation (Details          HTML     29K 
                Narrative)                                                       
59: R39         Stock Issuance (Details)                            HTML     32K 
60: R40         Stock Issuance (Details Narrative)                  HTML     28K 
61: R41         Business Segments (Details)                         HTML     68K 
62: R42         Business Segments (Details 1)                       HTML     38K 
63: R43         Related Party Transactions (Details Narrative)      HTML     30K 
64: R44         Commitments and Contingencies (Details)             HTML     36K 
65: R45         Commitments and Contingencies (Details Narrative)   HTML     27K 
66: R46         Subsequent Events (Details Narrative)               HTML     27K 
68: XML         IDEA XML File -- Filing Summary                      XML    105K 
67: EXCEL       IDEA Workbook of Financial Reports                  XLSX     51K 
15: EX-101.INS  XBRL Instance -- cdxc-20161001                       XML    996K 
17: EX-101.CAL  XBRL Calculations -- cdxc-20161001_cal               XML    125K 
18: EX-101.DEF  XBRL Definitions -- cdxc-20161001_def                XML    195K 
19: EX-101.LAB  XBRL Labels -- cdxc-20161001_lab                     XML    587K 
20: EX-101.PRE  XBRL Presentations -- cdxc-20161001_pre              XML    451K 
16: EX-101.SCH  XBRL Schema -- cdxc-20161001                         XSD    114K 
69: ZIP         XBRL Zipped Folder -- 0001654954-16-003772-xbrl      Zip     79K

‘EX-10.5’   —   Material Contracts

This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]

 C:   C: 
  SEC Connect  
 
Exhibit 10.5
AMENDMENT #1 TO EXCLUSIVE LICENSE AGREEMENT
This Amendment #1 (“First Amendment”) is made and entered into on December 15, 2015 (“First Amendment Effective Date”) by and between The Washington University, a corporation established by special act of the Missouri General Assembly approved February 22, 1853 and acts amendatory thereto, having its principal offices at One Brookings Drive, St. Louis, Missouri 63130 (hereinafter referred to as “WU”) and Chromadex, Inc., a corporation of the State of California, having a place of business at 10005 Muirlands Blvd., Suite G, Irvine, CA 92618 (hereinafter referred to as “Licensee”), each a “Party” or collectively the “Parties” of this Agreement.
WHEREAS, WU and Licensee entered into an Exclusive License Agreement (WU Contract No. 004446-011) on March 4, 2013 (“ELA”);
WHEREAS, certain information in the ELA was designated “TBD” in the “Milestone and Payments” table on page 1 and in the Exhibit F “Diligence Milestones” table;
NOW THEREFORE, in consideration of the foregoing and the agreements below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:
1. 
The Milestones and Payments table in the Preamble on page 1 is replaced in its entirety with the following:
Market
Milestone
Approximate
Timing
Payment
Field 1 (dietary supplement, sports nutrition, functional foods, skin care/cosmetic)
Commercial-scale production
12 months
$2K
Cumulative sales >3kg
18 months
$5K
$200K cumulative sales
24 months
$10K
$1M cumulative sales
36 months
$15K
Field 2 (food/beverage with FDA approval)
Cumulative sales >3kg
36 months
$5K
Cumulative sales >20kg
48 months
$10K
Field 3 (consumer foods)
Cumulative sales >3kg
24 months
$5K
$100K cumulative sales
36 months
$10K
$500K cumulative sales
48 months
$15K
Field 4 (research reagents)
$5K cumulative sales
24 months
$500
$10K cumulative sales
36 months
$1k
Field 5 (pharmaceutical)
IND application filed for neurological disease
EOY 2018
$20K
Phase 1 initiation
EOY 2019
$20K
Phase 2 initiation
EOY 2020
$25K
Phase 3 initiation
EOY 2021
$50K
NDA approval
EOY 2024
$100K
First commercial sale
EOY 2024
$250K
 
 
 
 
2. 
The Diligence Milestones table in Exhibit F is replaced in its entirety with the following:
Market
Milestone
Timing
Field 1 (dietary supplement, sports nutrition, functional foods, skin care/cosmetic)
Commercial-scale production
12 months
Cumulative sales >3kg
18 months
$200K cumulative sales
24 months
$1M cumulative sales
36 months
Field 2 (food/beverage with FDA approval)
Cumulative sales >3kg
36 months
Cumulative sales >20kg
48 months
Field 3 (consumer foods)
Cumulative sales >3kg
24 months
$100K cumulative sales
36 months
$500K cumulative sales
48 months
Field 4 (research reagents)
$5K cumulative sales
24 months
$10K cumulative sales
36 months
Field 5 (pharmaceutical)
IND application filed for neurological disease
EOY 2018
Phase 1 initiation
EOY 2019
Phase 2 initiation
EOY 2020
Phase 3 initiation
EOY 2021
NDA approval
EOY 2024
First commercial sale
EOY 2024
 
The Parties hereby agree to amend the terms of the ELA as provided above, effective as of the First Amendment Effective Date. Where the ELA is not explicitly amended, the terms of the ELA will remain in force. Definitions used in this First Amendment that are not otherwise defined herein shall have the meanings such terms are given in the ELA.
IN WITNESS WHEREOF, the authorized representatives of the parties hereto have executed this Amendment by affixing their signatures below on the date(s) indicated:
 
 Chromadex, Inc. 
 Washington University
 
 
 By: /s/ Troy Rhonemus
 Name: Troy Rhonemus 
 Title: COO 
 Date: 1/2/2016
 By: /s/ Nichole Mercier
 Name: Nichole Mercier, Ph.D.
 Title: Interim Director, OTM
 Date: 12.21.15
 
 
 
 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:11/10/168-K
For Period end:10/1/16
12/15/15
3/4/13
 List all Filings 

4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/06/24  ChromaDex Corp.                   10-K       12/31/23   95:9.1M                                   Workiva Inc Wde… FA01/FA
 3/08/23  ChromaDex Corp.                   10-K       12/31/22   93:9.2M                                   Workiva Inc Wde… FA01/FA
 3/14/22  ChromaDex Corp.                   10-K       12/31/21   91:9.9M                                   Workiva Inc Wde… FA01/FA
 3/12/21  ChromaDex Corp.                   10-K       12/31/20   98:7.7M                                   Blueprint/FA
↑Top
Filing Submission 0001654954-16-003772   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Mon., Apr. 29, 9:02:15.1am ET